Sardocor

Sardocor is a private, clinical-stage biotech subsidiary of the Medera Group, advancing a pipeline of cardiac gene therapies with three active FDA IND approvals. The company leverages foundational science from pioneers who established the cardiac gene therapy field over three decades ago and utilizes a proprietary intracoronary delivery method designed for enhanced efficacy and reduced side effects. Its lead programs target major unmet needs in heart failure (HFpEF and HFrEF) and Duchenne Muscular Dystrophy-associated cardiomyopathy (DMD-CM), with over 1,000 doses of its lead candidate, SRD001, already manufactured. Sardocor is currently pre-revenue and seeking investor partnerships to propel its innovative programs forward.

Proprietary intracoronary delivery method for targeted cardiac gene therapy, combined with the use of Novoheart's bioengineered human heart assays for disease modeling and therapeutic discovery.

The cardiac gene therapy space is emerging but competitive, with companies like Tenaya Therapeutics, Rocket Pharmaceuticals, and academic centers advancing programs. Sardocor differentiates with its specific intracoronary delivery focus and three active INDs, but faces competition from larger, well-funded biotechs and potential new entrants.